The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620405
Title:
The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Authors:
Huxley, N.; Crathorne, L.; Varley-Campbell, J. L.; Tikhonova, I.; Snowsill, T.; Briscoe, S.; Peters, J.; Bond, M.; Napier, Mark; Hoyle, M.
Abstract:
Colorectal cancer is the fourth most commonly diagnosed cancer in the UK after breast, lung and prostate cancer. People with metastatic disease who are sufficiently fit are usually treated with active chemotherapy as first- or second-line therapy. Targeted agents are available, including the antiepidermal growth factor receptor (EGFR) agents cetuximab (Erbitux(®), Merck Serono UK Ltd, Feltham, UK) and panitumumab (Vecitibix(®), Amgen UK Ltd, Cambridge, UK).
Citation:
The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. 2017, 21 (38):1-294 Health Technol Assess
Publisher:
NIHR
Journal:
Health technology assessment (Winchester, England)
Issue Date:
Jun-2017
URI:
http://hdl.handle.net/11287/620405
DOI:
10.3310/hta21380
PubMed ID:
28682222
Additional Links:
https://dx.doi.org/10.3310/hta21380
Note:
This report is freely available online. Click on the Additional Link above to access the full-text via the publisher's site.
Type:
Journal Article; Systematic review
Language:
en
ISSN:
2046-4924
Appears in Collections:
Oncology; 2017 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHuxley, N.en
dc.contributor.authorCrathorne, L.en
dc.contributor.authorVarley-Campbell, J. L.en
dc.contributor.authorTikhonova, I.en
dc.contributor.authorSnowsill, T.en
dc.contributor.authorBriscoe, S.en
dc.contributor.authorPeters, J.en
dc.contributor.authorBond, M.en
dc.contributor.authorNapier, Marken
dc.contributor.authorHoyle, M.en
dc.date.accessioned2017-09-19T09:57:55Z-
dc.date.available2017-09-19T09:57:55Z-
dc.date.issued2017-06-
dc.identifier.citationThe clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. 2017, 21 (38):1-294 Health Technol Assessen
dc.identifier.issn2046-4924-
dc.identifier.pmid28682222-
dc.identifier.doi10.3310/hta21380-
dc.identifier.urihttp://hdl.handle.net/11287/620405-
dc.description.abstractColorectal cancer is the fourth most commonly diagnosed cancer in the UK after breast, lung and prostate cancer. People with metastatic disease who are sufficiently fit are usually treated with active chemotherapy as first- or second-line therapy. Targeted agents are available, including the antiepidermal growth factor receptor (EGFR) agents cetuximab (Erbitux(®), Merck Serono UK Ltd, Feltham, UK) and panitumumab (Vecitibix(®), Amgen UK Ltd, Cambridge, UK).en
dc.language.isoenen
dc.publisherNIHRen
dc.relation.urlhttps://dx.doi.org/10.3310/hta21380en
dc.rightsArchived with thanks to Health technology assessment (Winchester, England)en
dc.subjectWessex Classification Subject Headings::Oncology. Pathology.en
dc.titleThe clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.en
dc.typeJournal Articleen
dc.typeSystematic reviewen
dc.identifier.journalHealth technology assessment (Winchester, England)en
dc.description.noteThis report is freely available online. Click on the Additional Link above to access the full-text via the publisher's site.en
dc.type.versionPublisheden
All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.